Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study-Reference-Cited by-同舟云学术

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

Published:2017-05-12 Issue:6 Volume:79 Page:1141-1149
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Leng Yun,Hou Jian,Jin Jie,Zhang Mei,Ke Xiaoyan,Jiang Bin,Pan Ling,Yang Linhua,Zhou Fang,Wang Jianmin,Wang Zhao,Liu Li,Li Wei,Shen Zhixiang,Qiu Lugui,Chang Naibai,Li Jianyong,Liu Jing,Pang Hongyan,Meng Haitao,Wei Peng,Jiang Hua,Liu Yan,Zheng Xiangjun,Yang Shifang,Chen Wenming^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-017-3310-0/fulltext.html

Reference18 articles.

1. Landgren O, Iskander K (2017) Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 281(4):365–382. doi: 10.1111/joim.12590

2. Kazandjian D, Landgren O (2016) A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol 43(6):682–689. doi: 10.1053/j.seminoncol.2016.10.008

3. Fang F, Wang AP, Yang SF (2005) Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Phamacologica Sinica 26:1373–1381. doi: 10.1111/j.1745-7254.2005.00206.x

4. Zhou H, Li J, Jian Y et al (2016) Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. Exp Hematol 44:125–131. doi: 10.1016/j.exphem.2015.10.004

5. Yan D, Ge Y, Deng H et al (2015) Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. Onco Targets Ther 8:1603–1610. doi: 10.2147/OTT.S73731

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Death Receptor 5 (DR5) for imaging and treatment of primary bone and soft tissue tumors: an update of the literature;Frontiers in Molecular Biosciences;2024-09-02

2. Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma;Cancer Cell International;2024-08-05

3. Multiple Mechanisms Contribute to Acquired TRAIL Resistance in Multiple Myeloma;2024-05-10

4. Aponermin: First Approval;Drugs;2024-03-05

5. Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics;Biochemical Pharmacology;2024-03